Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

August 1, 2027

Study Completion Date

March 31, 2028

Conditions
Lennox Gastaut SyndromeDravet SyndromeTuberous Sclerosis Complex
Interventions
DRUG

Cannabidiol

Oral Cannabidiol solution 100 mg/mL

Trial Locations (19)

10016

Clinical Trial Site, New York

21205

Clinical Trial Site, Baltimore

22601

Clinical Trial Site, Winchester

27708

Clinical Trial Site, Durham

28203

Clinical Trial Site, Charlotte

30912

Clinical Trial Site, Augusta

32806

Clinical Trial Site, Orlando

33136

Clinical Trial Site, Miami

33176

Clinical Trial Site, Miami

33606

Clinical Trial Site, Tampa

45219

Clinical Trial Site, Cincinnati

67214

Clinical Trial Site, Wichita

72758

Clinical Trial Site, Little Rock

77030

Clinical Trial Site, Houston

78681

Clinical Trial Site, Round Rock

90242

Clinical Trial Site, Downey

95817

Clinical Trial Site, Sacramento

02114

Clinical Trial Site, Boston

08901

Clinical Trial Site, New Brunswick

All Listed Sponsors
collaborator

Jazz Pharmaceuticals Research UK Limited

INDUSTRY

lead

Jazz Pharmaceuticals

INDUSTRY